

IN THE CLAIMS

Please cancel claims 1-6, and 11-19.

Please amend claims 7, 8, and 20 as follows:

7. (Amended) A binding compound comprising an antigen binding site from an antibody, which specifically binds to a mature polypeptide comprising at least 8 contiguous amino acid residues from[:

- a)] SEQ ID NO: 2[;
- b) SEQ ID NO: 6;
- c) SEQ ID NO: 13; or
- d) SEQ ID NO: 15].

8. (Amended) The binding compound of Claim 7, wherein[:

- a)] said binding compound is an Fv, Fab, or Fab2 fragment[;
- b) said binding compound is conjugated to another chemical moiety; or
- c) said antibody:
  - i) is raised against a polypeptide comprising a 12 consecutive amino acid segment of SEQ ID NO: 2, 6, 13, or 15;
  - ii) is raised against a mature IL-1 $\epsilon$ ;
  - iii) is raised to a purified rodent IL-1 $\delta$  or rodent or primate IL-1 $\epsilon$ ;
  - iv) is immunoselected;
  - v) is a polyclonal antibody;
  - vi) binds to a denatured IL-1 $\delta$  or IL-1 $\epsilon$ ;
  - vii) exhibits a K<sub>d</sub> to antigen of at least 30  $\mu$ M;
  - viii) is attached to a solid substrate, including a bead or plastic membrane;
  - ix) is in a sterile composition; or
  - x) is detectably labeled, including a radioactive or fluorescent label].

20. (Amended) A method of:

- A) making an antiserum comprising an antibody of Claim 7, comprising immunizing a mammal with an immunogenic amount of [:
  - a) a rodent IL-1 $\delta$  polypeptide;
  - b)] a peptide [sequence] comprising a 12 consecutive amino acid segment of SEQ ID NO: 2;
  - [c) a rodent or primate IL-1 $\epsilon$  polypeptide; or

9 d) a peptide sequence comprising a 12 consecutive amino acid segment of  
10 SEQ ID NO: 6, 13, or 15;]  
11 thereby causing said antiserum to be produced; or  
12

13 B) producing an antigen:antibody complex, comprising contacting [:

14 a)] a rodent IL-1 $\delta$  protein or peptide with [an antibody] a binding  
15 compound of Claim 7; [or

16 b) a rodent or primate IL-1 $\epsilon$  protein or peptide with an antibody of Claim  
17 7;]

18 thereby allowing said complex to form.

19  
1 Please add new claims 21-25 as follows:

1 21. (New) The binding compound of Claim 7, wherein said antibody is a  
2 polyclonal antibody.

1 22. (New) The binding compound of Claim 7, wherein said antibody is  
2 detectably labeled.

1 23. (New) The binding compound of claim 7, wherein said at least 8  
2 contiguous amino acid residues of SEQ ID NO:2 is selected from the group consisting of  
3 residues 8-24; 27-48; 56-73; 77-106; 108-125; 130-156; and 74-98.

1 24. (New) The binding compound of claim 7, wherein said polypeptide  
2 comprises at least 12 contiguous amino acid residues from SEQ ID NO: 2.

1 25. (New) The binding compound of claim 24, wherein said 12 consecutive  
2 amino acid segment is selected from:

3 (1) LeuCysPheArgMetLysAspSerAlaLeuLysValLeuTyrLeuHisAsn-Asn;

4 (2) IleSerValValProAsnArgAlaLeuAspAlaSerLeuSerProValIle-LeuGlyValGln;

5 (3) SerProValIleLeuGlyValGlnGlyGlySerGlnCys;

6 (4) ProIleLeuLysLeuGluProValAsnIleMetGluLeu;